Goodwin Procter LLP advised Vascular Biogenics Ltd. on the deal.Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT) announced the closing of its underwritten public offering of 6,901,790 ordinary…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
